Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service LAA occlusion & loop recorders cases in Delaware: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 3% on average (229 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 15 | 502 | 18% |
| 2020 | 13 | 390 | 20% |
| 2021 | 16 | 415 | 25% |
Left atrial appendage closure and implantable loop recorders: an older, Medicare-heavy population. Professional codes (what the surgeon bills): CPT 33340, 33285; the hospital bills MS-DRG 273, 274, 317.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 82% of the cases CMS names in Delaware; 10 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Pacemaker, ICD & CRT implantation | 13 | 724−4.8%/yr | −4.8%/yr | 4.30.8× | 0% | 790 in 2030+1.4%/yr |
| EP ablation |
LAA occlusion & loop recorders in every state, and its device makers · Every procedure market in Delaware · Every state · Compare with Florida
| 2024 |
| 625 |
| 35% |
| 2025 est. | ≈ 590 | – |
| 2026 est. | ≈ 630 | – |
| 2022 | 14 | 542 | 29% |
| 2023 | 17 | 640 | 32% |
| 2024 | 17 | 625 | 35% |
| 2025 from claims | – | 593 480–697 | 35% |
| 2026 forecast | – | 635 497–797 | 35% |
| 2027 forecast | – | 674 500–891 | 36% |
| 2028 forecast | – | 715 506–987 | 36% |
| 2029 forecast | – | 759 516–1,088 | 37% |
| 2030 forecast | – | 805 528–1,195 | 37% |
In 2025, 47% inpatient hospital, 22% hospital outpatient, 31% office.
| Forecast, Medicare FFS | Inpatient | Hospital outpatient | Office |
|---|---|---|---|
| 2026 · ~630 | ~310 | ~130 | ~190 |
| 2027 · ~670 | ~330 | ~140 | ~200 |
| 2028 · ~720 | ~350 | ~140 | ~220 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: inpatient hospital about 49% (47% in 2025), hospital outpatient about 20% (22% in 2025).
| +12%/yr |
| 3.8 |
| 18% |
| 18,100 in 2030+11%/yr |
| South Carolina | 71 | 3,614+14%/yr | +14%/yr | 4.7 | 11% | 6,460 in 2030+10%/yr |
| Virginia | 85 | 3,380+18%/yr | +18%/yr | 2.9 | 19% | 6,100 in 2030+10%/yr |
| Tennessee | 70 | 2,864+9.6%/yr | +9.6%/yr | 3.5 | 3% | 5,150 in 2030+10%/yr |
| Georgia | 70 | 2,787+8.8%/yr | +8.8%/yr | 2.8 | 7% | 5,510 in 2030+12%/yr |
| North Carolina | 76 | 2,760+8.6%/yr | +8.6%/yr | 2.4 | 7% | 4,660 in 2030+9.1%/yr |
| Oklahoma | 50 | 1,926+8.2%/yr | +8.2%/yr | 3.6 | 8% | 3,560 in 2030+11%/yr |
| Maryland | 56 | 1,696+8.1%/yr | +8.1%/yr | 1.8 | 35% | 3,080 in 2030+10%/yr |
| Mississippi | 37 | 1,533+9.3%/yr | +9.3%/yr | 3.6 | 28% | 2,480 in 2030+8.3%/yr |
| Alabama | 39 | 1,517+9.2%/yr | +9.2%/yr | 2.9 | 6% | 2,190 in 2030+6.3%/yr |
| Louisiana | 39 | 1,487+8.4%/yr | +8.4%/yr | 3.1 | 11% | 2,580 in 2030+9.6%/yr |
| Arkansas | 24 | 1,335+7.5%/yr | +7.5%/yr | 3.1 | 0% | 2,590 in 2030+12%/yr |
| Kentucky | 42 | 1,148+5.9%/yr | +5.9%/yr | 2.2 | 0% | 2,100 in 2030+11%/yr |
| West Virginia | 16 | 642+15%/yr | +15%/yr | 2.6 | 0% | 980 in 2030+7.4%/yr |
| District of Columbia | 8 | 352+11%/yr | +11%/yr | 5.1 | 43% | 630 in 2030+10%/yr |
| 7 |
| 268+0.4%/yr |
| +0.4%/yr |
| 1.40.4× |
| 0% |
| 330 in 2030+3.6%/yr |
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
Abbott leads with 76% of company spending on these surgeons in 2025, +63 pts on 2024.
In 2025, 4 companies reported engagement with Delaware’s surgeons worth $13K in consulting, speaking, meals and travel tied to these products, about $777 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 20 clearances and approvals in the category, 6 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.